ACCELERATING DEVELOPMENT AND
INCREASING AWARENESS AND ACCESS
OF PATIENTS WITH CANCER
TO IMMUNOTHERAPY

T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

4 June 2021,1:30 To 6:30 PM

European Academic Car-T Cells and IECs Clinical Trials

EHA Congress 9 -17 June

Presentation For T2EVOLVE at European Projects Session

22 To 25 June 2021

9th A .I .S, 2 Speakers from T2EVOLVE

CAR T-cell therapy

Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.

For additional information on CAR T-cell technology please contact UKW

Leadership

Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany

Prof Michael Hudecek, MD

CMC Project leader for the allogenic CAR-T program at SERVIER IRIS and EPFIA project leader T2Evolve, Suresnes Cedex, France 

Dr Hélène Negre

Funding

This Project Has Received Funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) Under Grant Agreement No. 853988.The JU Receives Support from thr European Union’s Horizon 2020 Research and Innovation Programme and EFPIA and JDRF INTERNATIONAL.

Share This